182 related articles for article (PubMed ID: 15055874)
1. Obstructing Crohn's disease of the duodenum: is surgery always mandatory?
Karaoglu AO; Yukselen V
Int J Clin Pract; 2004 Feb; 58(2):221-3. PubMed ID: 15055874
[TBL] [Abstract][Full Text] [Related]
2. Mesalamine for prophylaxis of small bowel Crohn's disease recurrence.
Bauer WM; Brzezinski A; Lashner BA
Curr Gastroenterol Rep; 1999 Oct; 1(5):377-83. PubMed ID: 10980975
[TBL] [Abstract][Full Text] [Related]
3. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
[TBL] [Abstract][Full Text] [Related]
4. Little benefit from mesalazine taken prophylactically after surgery for Crohn's disease.
Rutgeerts P
Gut; 2001 Apr; 48(4):452-3. PubMed ID: 11247886
[No Abstract] [Full Text] [Related]
5. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
6. Mesalazine as a maintenance treatment in Crohn's disease.
Sutherland LR; Steinhart AH
Gut; 1998 Jan; 42(1):143-4. PubMed ID: 9505902
[No Abstract] [Full Text] [Related]
7. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Feagan BG; Sandborn WJ
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
[TBL] [Abstract][Full Text] [Related]
8. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
9. Mesalamine derivatives in the treatment of Crohn's disease.
Harrell LE; Hanauer SB
Gastroenterol Clin North Am; 2004 Jun; 33(2):303-17, ix-x. PubMed ID: 15177540
[TBL] [Abstract][Full Text] [Related]
10. [Mesalazine and sulphasalazine for Crohn's disease: few indications, severe adverse reactions].
Uittenbogaart SB; Klemt-Kropp M
Ned Tijdschr Geneeskd; 2011; 155(48):A3842. PubMed ID: 22152414
[TBL] [Abstract][Full Text] [Related]
11. Mesalamine maintenance therapy for Crohn's disease.
Feagan BG; McDonald JW
Gastroenterology; 2001 Feb; 120(2):585-6. PubMed ID: 11271451
[No Abstract] [Full Text] [Related]
12. Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease.
Steinhart AH; Forbes A; Mills EC; Rodgers-Gray BS; Travis SP
Aliment Pharmacol Ther; 2007 Jun; 25(12):1389-99. PubMed ID: 17539978
[TBL] [Abstract][Full Text] [Related]
13. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease.
Feagan BG
Eur J Surg; 1998 Dec; 164(12):903-9. PubMed ID: 10029385
[No Abstract] [Full Text] [Related]
14. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
[TBL] [Abstract][Full Text] [Related]
15. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
[TBL] [Abstract][Full Text] [Related]
16. Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis.
Tsuboi R; Matsumoto S; Miyatani H; Mashima H
Intern Med; 2019 Mar; 58(5):649-654. PubMed ID: 30333413
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of 5-aminosalicylates for the maintenance of remission in Crohn's disease.
Akobeng AK
Am J Gastroenterol; 2011 Oct; 106(10):1857; author reply 1857-8. PubMed ID: 21979212
[No Abstract] [Full Text] [Related]
18. [A case of Crohn's disease that shows the improvement of the gastric disorder by the administration of mesalazine powder].
Nagamata H; Torii A; Izumi M; Anami M; Yamashita N; Inadama E; Toda G
Nihon Shokakibyo Gakkai Zasshi; 2000 Oct; 97(10):1261-6. PubMed ID: 11075590
[No Abstract] [Full Text] [Related]
19. Mesalamine in the treatment of active Crohn's disease.
Dignass A; Marteau P
Gastroenterology; 2005 Jan; 128(1):245-6; author reply 246. PubMed ID: 15633152
[No Abstract] [Full Text] [Related]
20. Decreased anti-Saccharomyces cerevisiae antibody titer by mesalazine in patients with Crohn's disease.
Oshitani N; Hato F; Matsumoto T; Jinno Y; Sawa Y; Hara J; Nakamura S; Seki S; Arakawa T; Kitano A; Kitagawa S; Kuroki T
J Gastroenterol Hepatol; 2000 Dec; 15(12):1400-3. PubMed ID: 11197050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
